- Home
- CRWD vs NVO Comparison
CRWD vs NVO Comparison
Compare CRWD & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRWD | NVO |
|---|---|---|
| Founded | 2011 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.8B | 199.4B |
| IPO Year | 2019 | 2001 |
Fundamental Metrics
Financial Performance| Metric | CRWD | NVO |
|---|---|---|
| Price | $256.31 | $38.95 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 53 | 14 |
| Target Price | ★ $246.15 | $45.80 |
| AVG Volume (30 Days) | 6.1M | ★ 8.5M |
| Earning Date | 12-01-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 3.25% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $4,812,005,000.00 | N/A |
| Revenue This Year | $24.84 | N/A |
| Revenue Next Year | $22.71 | $1.28 |
| P/E Ratio | $7,953.67 | ★ $13.60 |
| Revenue Growth | ★ 21.71 | N/A |
| 52 Week Low | $174.14 | $35.12 |
| 52 Week High | $786.00 | $64.16 |
Technical Indicators
Market Signals| Indicator | CRWD | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 44.02 |
| Support Level | $178.38 | $38.02 |
| Resistance Level | $286.99 | $39.58 |
| Average True Range (ATR) | 12.32 | 0.65 |
| MACD | -2.67 | 0.38 |
| Stochastic Oscillator | 53.22 | 71.92 |
Price Performance
Historical ComparisonAbout CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-native cybersecurity company specializing in security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform, which provides enterprises with a unified view to detect and respond to security threats across their IT infrastructure. The Austin, Texas-based firm was founded in 2011 and went public in 2019.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.